Abstract

REVIEW STUDY ON COMPARISION OF SAFETY AND EFFICACY OF EDARAVONE A NEUROPROTECTIVE DRUG IN INDIAN POPULATION STROKE PATIENTS

Shaik Tanisha Bibi*, B. Harsshene, Sreenu Thalla, N. Prathibha and Padmalatha Kantamaneni

Abstract

Edaravone a free radical scavenger is the only neuroprotective agent effective for both Amyloid lateral sclerosis and Acute ischemic stroke treatment. Free radicals play a crucial role in brain ischemic injury by exacerbating membrane damage through peroxidation of unsaturated fatty acids of cell membrane leading to neuronal death and brain edema. Hence use of a free radical scavenger is very much essential in such conditions. Oxidative stress is a viable target in stroke therapy which can be reduced by the use of edaravone. The studies we mentioned aims at the safety and efficacy of Edaravone in a group of Indian population of acute ischemic stroke patients. Study 1 was an open label prospective study which was conducted in the Department of Neurology, CSM Medical University, Lucknow, a tertiary health care centre in North India. The study was carried out between January and July 2008. Study 2 was a prospective open labeled, randomized controlled study conducted in the Department of Neurology, Chatrapathi Shahuji Medical University, Luck now, and a tertiary health care centre in North India. The study was conducted between May 2009 and May 2010. All the patients received 30mg of Edaravone dissolved in 100ml of normal saline infusion over 60 minutes twice for 14 days. The outcome assessment was done by using the Modified Rankin Scale (MRS) and the Barthel Index (BI). MRS score ≤ 2 at 90 days was considered to be favorable outcome. In study 1 and the mean MRS score decreased at day 7 to day 14 to day 30 to day 90(p

Keywords: Edaravone, neuroprotective drug, free radical scavenger, both ALS and AIS treatment.